Phase II investigational study of pembrolizumab combination with chemotherapy in platinum-sensitive recurrent low-grade serous ovarian cancer

Conditions

fallopian tube- and/or primary peritoneal cancer, recurrent platin sensitive low-grade serous ovarian-

Brief summary

12-month (48 weeks) progression free survival (PFS) rate

Detailed description

ORR, OS and PFS rate after 6, 12, 18 and 24 months, PFS and OS as time-to-event variables, Response rate (SD, PR or CR) after 6, 12, 18 and 24 months, Ki-67 expression <3.6% versus ≥3.6% and response rate and PFS, Safety Endpoints – safety of combination therapy (ctx and pembrolizumab) CTCAE v5.0 will be used as endpoint, Time of subsequent medical intervention, TFST and response (CR, PR, SD, PD) to first subsequent treatment, QoL (EORTC-QLQ-C30, EORTC-QLQ-OV-28) until 6 months after progress

Jacek P. Grabowski, Elena Ioana Braicu, Philipp Harter, Dario Zocholl, Fabian Schmeling et al. (9 authors)

Journal of Clinical Oncology2026-05-27

10.1200/jco.2026.44.16_suppl.5595

First results of the NOGGO PERCEPTION: Phase II investigational study of pembrolizumab in combination with chemotherapy in platinum-sensitive recurrent low-grade serous ovarian cancer.

Jacek Grabowski, Elena Ioana Braicu, Philipp Harter, Dario Zocholl, Lea-Jean Pietzke et al. (9 authors)

Journal of Clinical Oncology2025-05-28

10.1200/jco.2025.43.16_suppl.e17548

Interventions

DRUGKEYTRUDA 25 mg/mL concentrate for solution for infusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
12-month (48 weeks) progression free survival (PFS) rate	—

Secondary

Measure	Time frame
ORR, OS and PFS rate after 6, 12, 18 and 24 months, PFS and OS as time-to-event variables, Response rate (SD, PR or CR) after 6, 12, 18 and 24 months, Ki-67 expression <3.6% versus ≥3.6% and response rate and PFS, Safety Endpoints – safety of combination therapy (ctx and pembrolizumab) CTCAE v5.0 will be used as endpoint, Time of subsequent medical intervention, TFST and response (CR, PR, SD, PD) to first subsequent treatment, QoL (EORTC-QLQ-C30, EORTC-QLQ-OV-28) until 6 months after progress	—

Measure

Time frame

ORR, OS and PFS rate after 6, 12, 18 and 24 months, PFS and OS as time-to-event variables, Response rate (SD, PR or CR) after 6, 12, 18 and 24 months, Ki-67 expression <3.6% versus ≥3.6% and response rate and PFS, Safety Endpoints – safety of combination therapy (ctx and pembrolizumab) CTCAE v5.0 will be used as endpoint, Time of subsequent medical intervention, TFST and response (CR, PR, SD, PD) to first subsequent treatment, QoL (EORTC-QLQ-C30, EORTC-QLQ-OV-28) until 6 months after progress

—

Countries

Germany

Outcome results

None listed